Back to All Events

Panel Discussion: Creating Consensus on Lexicons, Standards & Frameworks for MCED and MRD Tests for Community Benefit

  • 2nd Annual LBx Surveillance and Early Detection Summit Boston, MA United States (map)

In this panel discussion, BLOODPAC members Angela Silvestro (Director, Companion Diagnostics, GSK) and Dan Stetson (Principal Scientist, AstraZeneca) will discuss:

  • Current standards and frameworks in development for MCED and MRD testing

  • Awareness, education and access coordination initiatives for MCED and MRD testing

  • The importance of standardizing terms in emerging areas of liquid biopsy use for stakeholders who use or interpret these tests

  • How standardizing early detection strategies impact the mitigation of the morbidities resulting from rare and currently unscreened cancers

  • Key next steps in advancing implementation of MCED and MRD tests

Source: https://lbx-surveillance-early-detection-summit.com/
Previous
October 4

Navigating a Path to Advance the Use of Liquid Biopsies for Early Cancer Screening and Detection (Panel Discussion)
Next
November 20

Moving Towards Global Harmonization of Liquid Biopsy Frameworks and Standards: The BLOODPAC Experience